Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program

Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Diabetes care (Impact Factor: 8.57). 12/2011; 35(2):363-6. DOI: 10.2337/dc11-1328
Source: PubMed

ABSTRACT We tested genetic associations with weight loss and weight regain in the Diabetes Prevention Program, a randomized controlled trial of weight loss-inducing interventions (lifestyle and metformin) versus placebo.
Sixteen obesity-predisposing single nucleotide polymorphisms (SNPs) were tested for association with short-term (baseline to 6 months) and long-term (baseline to 2 years) weight loss and weight regain (6 months to study end).
Irrespective of treatment, the Ala12 allele at PPARG associated with short- and long-term weight loss (-0.63 and -0.93 kg/allele, P ≤ 0.005, respectively). Gene-treatment interactions were observed for short-term (LYPLAL1 rs2605100, P(lifestyle*SNP) = 0.032; GNPDA2 rs10938397, P(lifestyle*SNP) = 0.016; MTCH2 rs10838738, P(lifestyle*SNP) = 0.022) and long-term (NEGR1 rs2815752, P(metformin*SNP) = 0.028; FTO rs9939609, P(lifestyle*SNP) = 0.044) weight loss. Three of 16 SNPs were associated with weight regain (NEGR1 rs2815752, BDNF rs6265, PPARG rs1801282), irrespective of treatment. TMEM18 rs6548238 and KTCD15 rs29941 showed treatment-specific effects (P(lifestyle*SNP) < 0.05).
Genetic information may help identify people who require additional support to maintain reduced weight after clinical intervention.

Download full-text


Available from: Jeanne M Mccaffery, Aug 21, 2015
1 Follower
  • Journal of pediatric endocrinology & metabolism: JPEM 02/2012; 25(1-2):1. DOI:10.1515/jpem-2012-0999 · 0.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is becoming an escalating global epidemic in many parts of the world and results in a huge rise of sanity costs due to its associate comorbidities. In this sense, body weight regulation depends on a combination of interactions between genetic and environmental factors. Among inheritance factors, body weight is normally a polygenic condition determined by the presence of genes of high prevalence but with a low relevant effect. In the last years, Candidate Genes Analyses and Genome Wide Association Studies (GWAS) have become very useful strategies to detect new polymorphisms and copy number variants (CNVs) associated with obesity and its related comorbidities. From these studies, more than a hundred genetic variants involved in metabolic pathways including adipogenesis, energy intake, lipolysis or energy expenditure have been found. These findings along with epigenetics and nutrigenetics are the basis to the development of new tools that would allow predicting individual obesity susceptibility and weight loss response.
    03/2012; 2(1). DOI:10.1007/s13679-012-0036-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan. Gradually accumulating discrepancies about its effect on cancer and obesity can be explained by the shortage of randomized clinical trials, differences between control groups (reference points), gender- and age-associated effects and pharmacogenetic factors. Studies of the potential antiaging effects of antidiabetic biguanides, such as metformin, are still experimental for obvious reasons and their results are currently ambiguous. Here we discuss whether the discrepancies in different studies are merely methodological or inherently related to individual differences in responsiveness to the drug.
    Aging 04/2012; 4(5):320-9. · 4.89 Impact Factor
Show more